Open the map

InsuletPODD

Diabetes & metabolic disease · NASDAQ · USA

$134.47
Up 0.1% todayClose

Down 52.7% this year and −15.0% since June 26, behind the life science sector at +10.7%. Insulet supplies 1 mapped company.

Market cap
$9.3B
This year
−52.7%
1 year
−57.1%
P/E
24.8
P/S
3.1
P/B
6.2

Price vs the life science sector

since Jun 26PODDLife science sector, equal weight
Insulet (PODD) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. PODD: −15.0% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.−20%−10%0%+10%Jun 26AugSepOct 8PODD −15.0%Sector +10.7% Insulet (PODD) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. PODD: −15.0% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.−20%−10%0%+10%Jun 26AugSepOct 8PODD−15.0%Sector+10.7%

Supply chain

1 customer
SUPPLIERS →→ CUSTOMERSNone mappedCVS Health (CVS)CVSCVS Health−0.2%PODDInsulet

Customers 1

Open the full chain →

About Insulet

Maker of Omnipod, a tubeless insulin pump that handles dosing automatically.

Theme exposure

DiabetesInsulin pumpsMedtech exposureInsulin deliveryDigital health

Products

  • Omnipod insulin pump
  • Automated insulin dosing

Competitors

Risks

  • Competition
  • Reimbursement changes

Same segment: Diabetes & metabolic disease

Treatment and monitoring of diabetes and metabolic disease, from insulin to glucose monitoring. Segment 1 of 8 in the Medicine, pharma & life science value chain.

Eli LillyLLY−1.6%DexComDXCM+0.1%

Compare PODD

Side by side with the largest companies in the same segment.

PODD vs LLYPODD vs DXCM

See where Insulet sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →